Overview
Autoimmune liver diseases encompass conditions such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes where immune mechanisms target liver tissue, leading to inflammation and damage. 5Diagnosis
Key Diagnostic Criteria: Presence of characteristic autoantibodies (e.g., antimitochondrial antibodies in PBC, antinuclear antibodies in AIH), elevated liver enzymes, and histological evidence of liver inflammation. 5
Recommended Tests: Serologic testing for specific autoantibodies, liver function tests (ALT, AST, ALP, GGT), imaging studies (ultrasound, MRCP), and liver biopsy for definitive diagnosis. 5
Grading: Histological grading using the Scheuer scoring system for PBC and the International Autoimmune Hepatitis Group (IAIHG) scoring system for AIH. 5Management
First-Line Treatments: Corticosteroids (e.g., prednisolone) for AIH, often in combination with immunosuppressants like azathioprine. 5
Adjunctive Treatments: Ursodeoxycholic acid (UDCA) for PBC to improve liver biochemistry and survival. 5
Monitoring: Regular monitoring of liver function tests, autoantibody levels, and clinical symptoms to adjust therapy. 5Special Populations
Pregnancy: Management requires careful consideration of immunosuppressive therapy risks; close monitoring and potential adjustments in treatment are necessary. 5
Overlap Syndromes: Recognition and management may switch between AIH and PBC; tailored therapy based on predominant features is crucial. 4Key Recommendations
Enhance Monitoring for Vaccine-Associated Hepatic Autoimmune Disorders: Implement enhanced surveillance protocols before and after vaccination, particularly for hepatitis B, COVID-19 mRNA, and papillomavirus vaccines. (Evidence: Moderate) 1
Evaluate Serum Vitamins and Homocysteine Levels: Assess serum vitamins A, E, and C, as well as homocysteine levels, in patients with autoimmune liver diseases to guide nutritional support and management strategies. (Evidence: Moderate) 2
Recognize and Manage Overlap Syndromes: Be vigilant for transitions between different autoimmune liver diseases (e.g., PBC to AIH) and adjust treatment accordingly to optimize patient outcomes. (Evidence: Weak) 4References
1 Jeong J, Jo H, Park J, Smith L, Rahmati M, Lee K et al.. Global Estimates of Vaccine-Associated Hepatic Autoimmune Disorders and Their Related Vaccines, 1968-2024: An International Analysis of the WHO Pharmacovigilance Database. International archives of allergy and immunology 2025. link
2 Li J, Tian S, Ci B, Xi Y, Deng X. Serum vitamins and homocysteine levels in autoimmune liver disease: A systematic review and meta-analysis. Immunity, inflammation and disease 2024. link
3 Bakhtawar J, Siraj S, Sulaiman H. Total Intravenous Anaesthesia <em>vs</em>. Inhalational Agents in a Patient with Autoimmune Liver Disease. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2023. link
4 Patel N, Amarapurkar D, Amarapurkar A. Primary biliary cirrhosis and autoimmune hepatitis switch over: report of 2 cases. Tropical gastroenterology : official journal of the Digestive Diseases Foundation 2005. link
5 Manns MP. Recent developments in autoimmune liver diseases. Journal of gastroenterology and hepatology 1997. link
6 Powell FC, Schroeter AL, Dickson ER. Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. The Quarterly journal of medicine 1987. link